Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

Eli Lilly And Co (NYSE:LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a report on gov.ie, a central portal for government services and information.

  • The plant itself will employ more than 300 once it's complete. In the meantime, Lilly plans to enlist some 500 temporary workers for the facility build.
  • The Limerick plant will boost Lilly's manufacturing network for biologic active ingredients, help meet "increased demand for existing Lilly products," and extend the geographic reach of the company's clinical pipeline. 
  • Lilly specifically singled out its "promising" Alzheimer's portfolio on the last point.
  • In a recent interview, Lilly could launch Alzheimer's hopeful donanemab toward the end of 2022, Anat Ashkenazi, Lilly's chief commercial officer, said
  • The anti-amyloid antibody, which would rival Biogen Inc's controversial Aduhelm (aducanumab), is up for accelerated approval. Lilly expects to complete its rolling FDA submission by the end of Q1 FY22.
  • Related: Lilly's Donanemab Lowers Alzheimer's-Associated Biomarkers In Patients With Early Disease.
  • The facility is expected to start the production of active pharmaceutical ingredients in 2022.
  • Lilly will submit a planning application with Limerick City and County Council in the next few weeks to win approval for the project.
  • Price Action: LLY shares are up 1.82% at $241.07 during the market session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.